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Aims: The aims of the study were to investigate the effects of nifedipine on potassium chloride (KCl)-evoked
rat uterine contractions on different days of pregnancy in vitro, and the alterations in the effects of nifedipine
on combination with terbutaline or progesterone.
Main methods: In rat myometrial rings taken on different days of pregnancy, rhythmic contractions were
evoked with KCl in an isolated organ bath.
Key ﬁndings: The relaxing effect of nifedipine was most expressed in the 25 mM KCl-induced uterine
contractions, reaching the maximum on the last day of pregnancy (day 22). This effect was decreased by
progesterone pretreatment in vivo. Synergism was observed in the uterus-relaxing effect of nifedipine+
terbutaline, though the extent of potentiation depended on the sequence of administration of the two
compounds. When terbutaline was added ﬁrst in a single dose, the maximal inhibitory effect of nifedipine
was lower. This decrease in the inhibition was suspended by a Ca2+-poor buffer, indicating the role of Ca2+
channel activating effect of terbutaline.
Signiﬁcance: It is concluded that the uterus-relaxing effect of nifedipine is weakened by progesterone and
may be enhanced by low concentrations of β-mimetics. However, the administration of terbutaline cannot
precede the administration of nifedipine.© 2009 Elsevier Inc. All rights reserved.Introduction
Uterine contractility is generated by contractions of the myometrial
smooth muscle cells that comprise most of the myometrial layer of the
uterine wall (Bursztyn et al. 2007). Depolarization of the cell membrane
initiates calcium ion (Ca2+) entry into the cells through voltage-operated
Ca2+ channels, leading to increase in the intracellular Ca2+ concentration
(CCa,i) and muscle contraction (Noble et al. 2009; Dolphin 2006).
The Ca2+ channels are complex proteins composed of ﬁve distinct
subunits encoded by multiple genes (Catterall et al. 2005). It was
demonstrated that the uterine smooth muscle possesses α1C-short and
α1C-long isoforms (Helguera et al. 2002). Dihydropyridine compounds,
such as nifedipine bind to the inside of the voltage-gated L-type
channels, inhibiting the action potential and the contractility. The
dihydropyridines are the most potent inhibitors of uterine tension
development among the Ca2+ entry blockers and are therefore of
considerable interest for both therapeutic and experimental purposes
(Garﬁeld 1990). Nifedipine and its analogs have recently been
considered as tools for tocolytic therapy (Moynihan et al. 2008; Oei
2006). To date, the changes in myometrial contractility to nifedipine
by pregnancy have not been investigated.36 62 545567.
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l rights reserved.β-adrenergic stimulants produce relaxation of the smooth muscle
by raising the level of intracellular cyclic AMP. Progesterone
pretreatment increases the expression of the β2-adrenergic receptor
(AR) during pregnancy and alters the effects of β2-AR agonists on the
pregnant myometrium; progesterone and its derivatives have been
considered as drugs against premature labor (Gálik et al. 2008;
Mackenzie et al. 2006). The addition of a β-agonist to a Ca2+
antagonist might be expected to increase the effect of the Ca2+
antagonist (Triggle 1978; Lever et al. 1984). The effects of combina-
tions of β2-AR agonists and Ca2+ channel blockers have previously
been investigated in the isolated trachea. It was shown that both
isradipine and nifedipine potentiated the relaxant action of terbuta-
line and salmeterol, respectively (Thirstrup et al. 1997).
One of the aims of the present study was an in vitro investigation
of the effects of nifedipine on the potassium chloride (KCl)-evoked rat
uterine contractions on different days of pregnancy in rat. As a further
aim, we set out to alter the effect of nifedipine by applying a
combination with terbutaline or progesterone.Materials and methods
All experiments involving animal subjects were carried out with
the approval of the Hungarian Ethical Committee for Animal Research
(registration number: IV/1758-2/2008).
Fig. 1. Inhibitory effect of nifedipine on contractions evoked by 100 mM (a) and 25 mM
(b) KCl in isolated pregnant rat uteri in vitro on different days of pregnancy.● day 15,▲
day 18, ▼ day 20, ♦ day 22.
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Mature female (180–200 g) andmale (240–260 g) Sprague–Dawley
rats were mated in a special mating cage. A metal door, which was
movablebya small electric engine, separated the rooms for themale and
female animals. A timer controlled the function of the engine. Since rats
are usually active at night, the separatingdoorwas opened before dawn.
Within 4–5 h after the possibility of mating, vaginal smears were taken
from the female rats and a sperm search was performed under a
microscope at a magniﬁcation of 1200 times. If the smear proved
positive, or if smear takingwas impossible because of anexisting vaginal
sperm plug, the female rats were separated and were regarded as ﬁrst-
day pregnant animals.
Isolated organ studies
Uterus preparation
Uteri were removed from rats (250–350 g) on day 15, 18, 20 or 22
of pregnancy. Muscle rings 5 mm long were sliced from the uterine
horns and mounted vertically in an organ bath containing 10 ml de
Jongh solution (composition: 137 mM NaCl, 3 mM KCl, 1 mM CaCl2,
1 mM MgCl2, 12 mM NaHCO3, 4 mM NaH2PO4, 6 mM glucose,
pH=7.4). The organ bath was maintained at 37 °C and carbogen (95%
O2+5% CO2) was bubbled through it. After mounting, the rings were
equilibrated for about 1 h before the experiments were undertaken,
with a solution change every 15 min. The initial tension of the
preparation was set to about 1.25 g, which was relaxed to about 0.5 g
at the end of equilibration. The tension of the myometrial rings was
measured with a gauge transducer (SG-02; Experimetria Ltd.,
Budapest, Hungary) and recorded with a SPEL Advanced ISOSYS
Data Acquisition System (Experimetria Ltd., Budapest, Hungary).
Nifedipine studies
Contractions were elicited with 25 mM or 100 mM KCl, and
noncumulative dose–response curves were constructed in each experi-
ment in the presence of nifedipine (10−11–10−6 M) (Sigma-Aldrich,
Budapest, Hungary). Following the addition of each concentration of
nifedipine, recording was performed for 300 s. Concentration–response
curves were ﬁtted, and areas under curves (AUCs) were evaluated and
analyzed statistically with the Prism 4.0 (Graphpad Software Inc. San
Diego, CA, USA) computer program. From the AUC values, the maximal
inhibitory effect of nifedipine on a given day of pregnancy (Emax) and the
concentration of nifedipine eliciting 50% of the maximal inhibition of
uterine contraction (EC50)were calculated. For statistical evaluations, data
were analyzed by the ANOVA Neuman–Keuls test.
Nifedipine combination with terbutaline
Uteri were removed from rats (250–350 g) on day 22 of pregnancy
and mounted vertically in the organ bath as described above.
Contractions were elicited with 25 mM KCl, and cumulative dose–
response curves were constructed in each experiment in the presence
of nifedipine (10−11–10−6 M) and terbutaline (Sigma-Aldrich,
Budapest, Hungary) (10−7 M) or terbutaline (10−10–10−4 M) and
nifedipine (10−7 M). The effects of the nifedipine+terbutaline
combination were also investigated in the absence of Ca2+ ion in
vitro. De Jongh solution containing 0.5 mM Ca2+ ion was used to
induce a low Ca2+ environment. After the equilibration period, the
normal De Jongh solution was changed to the low Ca2+-containing
solution. The Emax and EC50 values of the curves obtained with the
combinations were calculated. For statistical evaluations, data were
analyzed through the unpaired t test.
Progesterone treatment
The progesterone treatment of the pregnant animals was started
on day 15 of pregnancy. Progesterone was dissolved in corn oil andinjected subcutaneously every day up to day 21 in a dose of 0.5 mg/
0.1 ml. On day 22, the uterine samples were collected and the
contractility studies (25 mM KCl) were carried out with nifedipine as
described above.
Results
The 25 mM and 100 mM KCl-stimulated uterine contractions were
inhibited concentration-dependently bynifedipine in the rangeof 10−11–
10−5M (Fig. 1a, b). As concerns the contractions induced by 100mMKCl,
the calculated EC50 was lower on day 18 than on day 15 (Table 1), but
there were no changes on the other days. There were signiﬁcant changes
in Emax on days 18, 20 and 22 as compared that on day 15. In the presence
of 25 mM KCl, the maximal relaxing effect of nifedipine was signiﬁcantly
greater on days 20 and 22 than on day 15. There were no signiﬁcant
changes in EC50 (Table 2).
The progesterone pretreatment decreased the maximal inhibitory
effect of nifedipine on day 22 and more than doubled its EC50 (Fig. 2,
Table 3).
The concentration–response curves for nifedipine in the presence
of 10−7 M terbutaline were shifted to the left and a decrease in the
maximal inhibitory effect was observed (Fig. 3a, Table 4a). In the
presence of 0.5 mM Ca2+ (Ca2+-poor buffer), terbutaline did alter the
effect of nifedipine (Fig. 3b, Table 4b).
Table 1
EC50 andEmax values of curves of uterine relaxation inducedbynifedipine (10−11–10−6M) in
the presence of 100 mM KCl.
Day of pregnancy EC50 (M±S.E.M.) Emax (%±S.E.M.)
15 6.8×10−8±1.1×10−8 62.7±2.7
18 1.5×10−7±4.7×10−8⁎⁎⁎ 46.9±3.6⁎
20 3.9×10−8±1.1×10−8 ns 39.6±4.4⁎
22 1.2×10−8±1.1×10−8 ns 41.7±4.3⁎
On each day, the level of signiﬁcance relates to the comparison with the value on day 15.
S.E.M.: standard error of the mean; ns: not signiﬁcant, ⁎p<0.05, ⁎⁎⁎p<0.001.
Fig. 2. Inhibitory effect of nifedipine on contractions evoked by 25 mM KCl with or
without progesterone pretreatment on day 22. ▲ nifedipine, ● after progesterone
pretreatment.
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of 10−7M nifedipine were also shifted to the left, but the this shift was
greater than that of the nifedipine curve by terbutaline. Nifedipine
also signiﬁcantly increased the Emax of terbutaline (Fig. 4a, Table 5a).
In the Ca2+-poor buffer, the presence of nifedipine increased the EC50
of terbutaline, but did not alter its Emax (Fig. 4b, Table 5b).
Discussion
High K+ stimulation, which provokes membrane depolarization
and uterine contractions, is the most common method for the
introduction of Ca2+ into cells without receptor stimulation. There
are a number of data relating to the use of different concentrations of
KCl (from low to high K+) to evoke contraction in vitro by opening
voltage-gated Ca2+ channels, though it is not clear which of these
concentrations causes rhythmic contractions of the uterus providing
an appropriate model for investigation of the pregnant uterus-
relaxing effects.
We found that in the presence of 25mMKCl the uterine contractions
were rhythmic and the relaxing effect of nifedipinewas very highon the
last day of pregnancy. With 100 mM KCl, however, the contractions
became spastic and the inhibitory action of nifedipine was highest on
day 15, but was later quite weak. These results led us to conclude that
stimulation with 25 mM KCl is much more appropriate for investiga-
tionsof the actionof theCa2+channel blockernifedipine. As the relaxing
effect of nifedipine was highest on the last day of pregnancy, further
experiments were carried out on day 22.
It was earlier demonstrated that the myometrial dihydropyridine
binding is increased more than 3-fold at the end of pregnancy in the
rat (Mershon et al. 1994), and this result was supported by our
ﬁndings. However, others found that the protein expressions and
mRNA levels of the pore-forming α1-subunits of the Ca2+ channels
were not altered by pregnancy either in rats or in humans (Batra and
Popper 1989 Helguera et al. 2002). It is known that the Cav1.2
channels possess splice variants in the cardiac muscle, which have
different pharmacological and electrophysiological properties (Liao
et al. 2005). So far, such variants have not been discovered in the
myometrium, but the apparent contradictions observed between the
above-mentioned papers and our result might be explained by the
existence of putative channel splice variants in the pregnant uterus.
The activity of the Cav1.2 channel is regulated by several factors
(Kobayashi et al. 2007). In our study, two of them were investigated
with regard to how to inﬂuence the uterus-relaxing effect of
nifedipine in vitro. Progesterone is regarded as a preventive drugTable 2
EC50 andEmax values of curves of uterine relaxation inducedbynifedipine (10−11–10−6M) in
the presence of 25 mM KCl on different days of pregnancy.
Day of pregnancy EC50 (M±S.E.M.) Emax (%±S.E.M.)
15 4.8×10−8±1.4×10−7 61.7±1.9
18 4.7×10−8±1.1×10−8 ns 61.8±2.9 ns
20 7.4×10−8±2.4×10−8 ns 47.0±3.1⁎⁎
22 1.03×10−7±3.6×10−8 ns 84.6±2.6⁎⁎⁎
On each day, the level of signiﬁcance relates to the comparison with the value on day 15.
S.E.M.: standard error of the mean; ns: not signiﬁcant, ⁎⁎p<0.01, ⁎⁎⁎p<0.001.against premature labor, especially in late-preterm birth (Borna and
Sahabi 2008). Unfortunately, the in vivo progesterone pretreatment
decreased themaximal inhibitory effect of nifedipine and increased its
EC50. The uterine smooth muscle possesses α1C-long and α1C-short
isoforms of the L-type Ca2+ channel. In the presence of the long
isoform, the channel has lower activity than with the short isoform. In
the pregnant rat uterus, progesterone and estrogen enhance the
expressions of the α1C-long and α1C-short isoforms, respectively, of the
L-type Ca2+ channels (Helguera et al. 2002). These facts explain why
progesterone pretreatment worsened the relaxing effect of nifedipine.
Accordingly we presumed that a Ca2+ channel blocker+progesterone
combination might not have any beneﬁt in clinical practice.
The other investigated factor which regulates the Cav1.2 channel
was the β2-adrenergic system. We found synergism in the uterus-
relaxing effect of nifedipine and the β2-AR agonist terbutaline,
although the extent of potentiation depended on the sequence of
administration of the two compounds. When terbutaline was added
ﬁrst in a single dose, synergism was found in EC50 (the nifedipine
curve was shifted to the left), but the maximal inhibitory effect of
nifedipine was lower. When nifedipine was administered ﬁrst, the
relaxing effect of terbutaline was obviously stronger.
It is known that stimulation of β2-ARs activates G-proteins and
increases the intracellular cAMP level. cAMP activates protein kinase A
the activated form of which phosphorylates the Cav1.2 channels. This
mechanism is well known in the heart muscle (Kamp and Hell 2000)
and it is very probably similar in the pregnantmyometrium. The entry of
the Ca2+ into the cells through the voltage-gated Ca2+ channel is one of
the crucial factors in the generation of smooth muscle contraction.
Terbutaline possibly activates the Cav1.2 channels and decreases the
maximal relaxing effect of nifedipine. The resultant effect of the increase
of cAMP level and activation of Cav1.2 channels causes aweaker smooth
muscle relaxation. In the opposite case, whennifedipine is administered
ﬁrst, the Cav1.2 channels are blocked; hence, there is only a low
possibility that terbutaline can activate them.Table 3
EC50 andEmax values of curves of uterine relaxation inducedbynifedipine (10−11–10−5M) in
the presence of 25 mM KCl on day 22 after progesterone pretreatment.
EC50 (M±S.E.M.) Emax (%±S.E.M.)
Nifedipine 9.7×10−8±2.8×10−8 87.3±2.2
Nifedipine+progesterone 2.8×10−7±4.9×10−8⁎⁎ 81.9±8.7 ns
S.E.M.: standard error of the mean; ns: not signiﬁcant, ⁎⁎p<0.01.
Fig. 3. Effect of the nifedipine+terbutaline combination on the 25 mM KCl-evoked
contractions in vitro on day 22. ■ nifedipine; ▲ nifedipine and terbutaline (10−7 M) in
1 mM Ca2+-containing buffer; □ nifedipine; Δ nifedipine+terbutaline (10−7 M) in
0.5 mM Ca2+-containing buffer.
Fig. 4. Effect of the nifedipine+terbutaline combination on the 25 mM KCl-chloride
evoked contractions in vitro on day 22. (a) ■ terbutaline; ▲ terbutaline+nifedipine
(10−7 M) (b) in 0.5 mM Ca2+-containing buffer (□ terbutaline; Δ terbutaline+
nifedipine (10−7 M).
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between the two compounds was investigated in Ca2+-poor buffer. A
Ca2+-poor environment theoretically decreases the terbutaline-
induced Ca2+ inﬂux and may alter the extent of the synergism. The
Ca2+-poor environment shifted the nifedipine dose–response curveTable 4
EC50 and Emax values of curves of uterine relaxation induced by the nifedipine+
terbutaline combination in the presence of 25 mM KCl on day 22 at 1 mM (a), 0.5 mM
(b) Ca2+.
EC50 (M±S.E.M.) Emax (%±S.E.M.)
a
Nifedipine 7.9×10−8±1.3×10−8 82.9±1.4
Nifedipine+terbutaline (10−7 M) 7.0×10−10±1.2×10−10⁎ 68.0±4.5⁎⁎
b
Nifedipine 4.0×10−9±2.1×10−9 89.2±2.1
Nifedipine+terbutaline (10−7 M) 1.6×10−9±7.3×10−10 ns 92.6±0.4 ns
The level of signiﬁcance relates to the comparison with the values for nifedipine and
terbutaline. S.E.M.: standard error of the mean; ns: not signiﬁcant, ⁎p<0.05, ⁎⁎p<0.01.to the left, and the maximal inhibitory effect of nifedipine was so high
that its effect could not be enhanced by terbutaline. In contrast, the
Ca2+-poor environment shifted the terbutaline dose–response curve
to the left, but nifedipine was able to enhance the shift. However, it
could not increase the maximal uterus-relaxing effect of terbutaline,Table 5
EC50 and Emax values of curves of uterine relaxation induced by the nifedipine+
terbutaline combination in the presence of 25 mM KCl on day 22 at 1 mM (a), 0.5 mM
(b) Ca2+.
EC50 (M±S.E.M.) Emax (%±S.E.M.)
a
Terbutaline 6.9×10−7±1.7×10−7 74.6±2.8
Terbutaline+nifedipine (10−7 M) 8.3×10−10±1.6×10−10⁎⁎ 90.8±0.8⁎⁎⁎
b
Terbutaline 1.5×10−7±1.6×10−10 97.6±1.1
Terbutaline+nifedipine (10−7 M) 5.3×10−9±2.1×10−9⁎⁎ 95.4±1.1 ns
The level of signiﬁcance relates to the comparison with the values for nifedipine and
terbutaline. S.E.M.: standard error of the mean; ns: not signiﬁcant, ⁎⁎p<0.01,
⁎⁎⁎p<0.001.
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These results indicate that, in a Ca2+-poor environment, terbutaline is
not able to worsen the maximal effect of nifedipine, which suggests
the role of the Ca2+ inﬂow in the weakening effect of terbutaline.
Conclusions
In the light of our results, we can conclude that the uterus-relaxing
effect of nifedipine is markedly increased on the last day of pregnancy
in the rat. In vivo progesterone treatment reduces the relaxant effect
of nifedipine on contracted uterine muscle. The combination of
nifedipine+terbutaline may be beneﬁcial to enhance the myometrial
relaxation, but our results indicate that the administration of
terbutaline cannot precede that of nifedipine.
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